Begur & Partners has advised Colossa Ventures LLP on its equity investment in Ahammune Biosciences Private Limited.

The transaction team was led by Rajesh Begur (Founder &Managing Partner) with support from Raman Kukreja (Associate).

Colossa Ventures participated in the $5 million Series A funding round for Ahammune Biosciences, a Pune-based clinical-stage therapeutics company specializing in treatments for chronic skin diseases. The round was led by pi Ventures and included other investors such as Capital2B, Bipin Agarwal, Unicornus Maximus LLP, and existing backers like Ideaspring Capital, Kotak Alternate Assets, Legacy Assets LLP, and Indian Angel Network (IAN) .

Ahammune plans to utilize the funds to conduct Phase II human clinical trials for its lead drug candidate targeting vitiligo, an autoimmune skin condition with no current cure. The company's small molecule therapeutic aims to halt the progression of depigmented patches and stimulate melanocyte function to restore skin pigmentation, all without causing generalized immunosuppression

Based in Pune, Ahammune Biosciences is an innovation-led drug discovery company started in 2016 which focuses on developing new treatment options for immune mediated diseases of the skin. Their current program is on the depigmenting disorder, Vitiligo.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.